Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Gustavo A.B. Fernandes"'
Autor:
Gustavo A.B. Fernandes, João Paulo S. Fernandes, Leandro J S Lima, Richardt G. Landgraf, Maristella A. Landgraf, Aleksandro Martins Balbino, Michele F Corrêa, Eliane Gomes
Publikováno v:
Cellular Physiology and Biochemistry, Vol 54, Iss 6, Pp 1163-1176 (2020)
BACKGROUND/AIMS: Histamine is an important chemical transmitter involved in inflammatory processes, including asthma and other chronic inflammatory diseases. Its inflammatory effects involve mainly the histamine H4 receptor (H4R), whose role in sever
Autor:
João Paulo S. Fernandes, Álefe Jhonatas Ramos Barbosa, Gustavo A.B. Fernandes, Michelle Fidelis Corrêa, Jillian G. Baker
Publikováno v:
Chemical Biology & Drug Design. 93:89-95
Histamine is a transmitter that activates the four receptors H1 R to H4 R. The H3 R is found in the nervous system as an autoreceptor and heteroreceptor, and controls the release of neurotransmitters, making it a potential drug target for neuropsychi
Autor:
Gustavo A.B. Fernandes, Michelle Fidelis Corrêa, Cecília M S Q Aranha, Holger Stark, David Reiner, Marina T. Varela, João Paulo S. Fernandes
Publikováno v:
Journal of Chemical Sciences. 132
Histamine and dopamine neuronal pathways display interesting overlapping in the CNS, especially in the limbic areas, making them very attractive to designing drugs with synergistic and/or additive effects. The roles of these systems to treat schizoph
Autor:
João Paulo S. Fernandes, György M. Keserű, Michel Bouvier, Dóra J. Kiss, Marina T. Varela, Claudio M. Costa-Neto, Sarah C. Simões, Jhonatan Christian Maraschin, André L. Balico-Silva, Michelle Fidelis Corrêa, Lucas T. Parreiras-e-Silva, Gustavo A.B. Fernandes
Publikováno v:
Bioorganic & Medicinal Chemistry. 30:115924
Histamine acts through four different receptors (H1R-H4R), the H3R and H4R being the most explored in the last years as drug targets. The H3R is a potential target to treat narcolepsy, Parkinson’s disease, epilepsy, schizophrenia and several other
Publikováno v:
European Journal of Pharmaceutical Sciences. 143:105171
Cardiovascular diseases (CVDs) present high prevalence rates in the current world. It is estimated that approximately one-third of the global deaths are related to CVDs, and thus there is still a need for novel drugs to treat these disorders. We sere